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Novel mutation in MCT8 gene 
in a Brazilian boy with thyroid 
hormone resistance and severe 
neurologic abnormalities 
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SUMÁRIO
O MCT8 é um transportador celular de hormônios tireoidianos, importante para sua ação e 
metabolização. Relatamos o caso de um menino com a nova mutação inativadora 630insG no 
éxon 1 do MCT8. O paciente caracterizou-se por grave comprometimento neurológico (inicial-
mente com hipotonia global, evoluindo com hipertonia generalizada), crescimento normal nos 
dois primeiros anos de vida, reduzido ganho ponderal e ausência dos sinais e sintomas típicos 
de hipotireoidismo. A sua avaliação sérica revelou elevação do T3, redução do T4 total e livre e 
TSH levemente aumentado. O tratamento com levotiroxina melhorou o perfil hormonal tireoi-
diano, mas não modificou o quadro clínico do paciente. Esses dados reforçam o conceito de 
que o papel do MCT8 é tecido-dependente: enquanto os neurônios são altamente dependentes 
do MCT8, o osso, o tecido adiposo, o músculo e o fígado são menos dependentes do MCT8 e, 
portanto, podem sofrer as consequências da exposição a níveis séricos elevados de T3. Arq Bras 
Endocrinol Metab. 2011;55(1):60-6
SUMMARY
MCT8 is a cellular transporter of thyroid hormones important in their action and metabolization. 
We report a male patient with the novel inactivating mutation 630insG in the coding region in 
exon 1 of MCT8. He was characterized clinically by severe neurologic impairment (initially with 
global hypotonia, later evolving with generalized hypertonia), normal growth during infancy, 
reduced weight gain, and absence of typical signs and symptoms of hypothyroidism, while 
the laboratory evaluation disclosed elevated T3, low total and free T4, and mildly elevated TSH 
serum levels. Treatment with levothyroxine improved thyroid hormone profile but was not able 
to alter the clinical picture of the patient. These data reinforce the concept that the role of MCT8 
is tissue-dependent: while neurons are highly dependent on MCT8, bone tissue, adipose tissue, 
muscle, and liver are less dependent on MCT8 and, therefore, may suffer the consequences of 
the exposition to high serum T3 levels. Arq Bras Endocrinol Metab. 2011;55(1):60-6
INTRODUCTION
Iodothyronine deiodinases are capable of activating or inactivating thyroid hormones (TH) (1). Type 2 
deiodinase (D2) removes an outer ring iodine atom, 
allowing the conversion of tetraiodothyronine (T4, or 
thyroxine) into triiodothyronine (T3), the active form 
of TH (1). On the other hand, the inactivation of T4 
to reverse T3 (rT3) and of T3 to T2 depends on the 
internal ring deiodination by type 3 iodothyronine de-
iodinase (D3). Type 1 iodothyronine deiodinase (D1) 
catalyzes the removal of inner or outer ring iodine at-
oms and therefore generates T3, rT3, or T2, depend-
ing on the substrate (1). In humans most circulating T3 
arises from T4 by the actions of D1 in the liver and kid-
ney, although D2 in the skeletal muscle also contributes 
(1). Hepatic D1 is involved in the clearance of rT3 into 
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T2, while D2 controls the intracellular concentration 
of T3 (1). D2 is responsible for the local generation 
of T3 when there is deprivation of T4, protecting vital 
organs (like the brain, for example) during periods of 
hypothyroidism (1). D3 is the only enzyme capable of 
degrading TH with an important role in the negative 
control of tissue and serum T3 levels (2).
The biological activity of TH is related to intracellu-
lar T3 concentration, which depends on the concen-
tration of circulating T4 and T3, the activity of deio-
dinases D1 and D2, and the activity of transporters 
responsible for the influx and/or efflux of T3 and T4 
(2). The monocarboxylate transporter 8 (MCT8) is an 
active transporter highly specific for TH present in di-
fferent tissues, including the brain, where it is expressed 
specifically by TH-sensitive neuronal populations (2). 
Friesema and cols. were the first to demonstrate that rat 
MCT8 facilitates the transport of iodothyronines into 
Xenopus laevis oocytes injected with the mRNA coding 
for this transporter (3). Subsequent studies demonstra-
ted the role of MCT8 in the TH transport in human 
tissues, particularly the brain (4,5). Later, Friesema and 
cols. showed that human MCT8 stimulates cellular up-
take of T4 and T3, but does not seem to be important 
for rT3 and T2 transportation (6). Importantly, they 
also demonstrated that MCT8 increases iodothyroni-
ne metabolism by deiodinases, a direct evidence that 
MCT8 increases the intracellular availability of these 
substrates (6). MCT8 and D2 seem to act synchroni-
cally since the treatment with T4 of cells co-expressing 
MCT8 and D2 results in increased T3 production and 
hormone responsiveness (1). 
The expression of MCT8 in the choroid plexus and 
in large capillaries indicates that it is involved in the 
transport of TH across the blood–brain barrier and the 
blood–cerebrospinal fluid barrier (2). MCT8 is pre-
sent in neurons and astrocytes of the paraventricular 
and infundibular nuclei, and in tanycytes located in the 
central lining of the third ventricle (these cells are in 
close contact with the cerebrospinal fluid, hypothala-
mus and median eminence and probably supply T3 to 
the central nervous system) (2). In neurons, MCT8 is 
important for the uptake of T3 produced from T4 in 
neighboring astrocytes that express D2. Neurons are 
the primary targets for TH action in the developing 
brain, and mutations in gene MCT8 deprive neurons of 
essential T3 and result in psychomotor retardation (2). 
The action of T3 on neurons is controlled by the local 
inactivation of T3 by D3. Therefore a defect in MCT8 
also reduces the inactivation of T3, resulting in increa-
sed serum T3 levels (2). 
The MCT8 gene consisting of six exons is located 
on the X chromosome (Xq13.2) and codes for a pro-
tein of 539 or 613 aminoacids depending on which of 
the two possible translation start sites is used. MCT8 
has 12 putative transmembrane domains (2). The hu-
man MCT8 gene was cloned in 1994 (2).
The inactivating mutations of MCT8 are associated 
to a severe neurologic dysfunction and high serum T3, 
that constitute the Allan-Herndon-Dudley syndro-
me (MIM 309600) (7). In addition to mutations in 
thyroid hormone receptor, the inactivating mutations 
of MCT8 constitute another cause of TH resistance (2).
In this article we describe a new MCT8 mutation 
identified on a male patient with severe neurological 
impairment and high serum T3 concentration.
SUbjeCT AND MeThODS
A male patient aged 12.25 years was first evaluated 
at our Unit of Pediatric Endocrinology when he was 
9 months old. The patient was referred to us due to 
neurologic delay, generalized hypotonia, strabismus, 
brain malformation, and abnormal thyroid profile. His 
mother was 22 years old when she became pregnant. 
Pregnancy and delivery were uneventful. Gestational 
age was of 40 weeks and the Apgar score in the first 
and fifth minutes was respectively 8 and 9. His birth 
weight (3096 g), body length (51 cm), and head circu-
mference (35 cm) were normal. His parents are healthy 
and nonconsanguineous. His two brothers are healthy. 
There was no familial history of neurological impair-
ment or of thyroid diseases. His neurological develo-
pment was impaired since the first months of life: the 
patient has never been able to control his head or to 
sit, showed few reactions to external stimuli and little 
communication with his parents and medical person-
nel. On the other hand, he could breast-feed efficiently. 
His parents described that he slept during the day and 
was awake at night what suggested a disruption of the 
wake-sleep cycle. His movements were uncoordinated. 
The auxological evaluation at the age of 9 months sho-
wed normal body length (74.5 cm; + 0.89 SDS), poor 
weight gain (9.0 kg; - 0.36 SDS), and normal head 
circumference (46 cm; +0.50 SDS). The disproportion 
between his stature and weight resulted in a thin appe-
arance. Physical exam showed asymmetry of the skull. 
In spite of a global hypotonia his upper right limb was 
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hypertonic. No goiter was found, nor were any clini-
cal characteristic of hypothyroidism noted. His cardiac 
rhythm was normal (76 bpm).
The global hypotonia noted during the first year 
of life gave rise to a generalized hypertonia with spas-
tic quadriplegia. During his follow-up a severe visual 
impairment was identified. The patient evolved with a 
crisis first noted when he was 2 years old characterized 
by fixed and deviated eyes, deviation of his head, loss 
of consciousness, and hypertonia of all four limbs. The 
crises were provoked by emotional stress or by crying. 
Initially, the crises occurred two to three times per week 
but the frequency increased up to two to three times 
per day, which prompted the introduction of anticon-
vulsant therapy. 
While his growth was normal during the first 20 
months of life (stature at 20 months = 85.0 cm; + 0.33 
SDS), his weight-gain worsened continuously (weight 
at 20 months = 10.0 kg; - 1.82 SDS). However, from 
20 months on both growth and weight-gain were im-
paired. The first teeth eroded after 16 months of life.
His first thyroid evaluation, performed when he was 
7 months old, disclosed high serum T3, reduced total 
and free T4, and TSH mildly increased (Table 1).
As clinical and hormonal features suggested a mu-
tation of MCT8 a molecular study was performed on 
the patient, his mother, and his brother, after informed 
consent was obtained from his parents. Genomic DNA 
was isolated from peripheral blood according to stan-
dard procedures (8). PCR from all exons were ampli-
fied individually, as previously described and directly se-
quenced (ABI PRISM 3130 xl, Perkin-Elmer Applied 
Biosystems, Foster City, California, USA) (5).
ReSULTS
In the neonatal period, screening for congenital hypo-
thyroidism was normal. Laboratory evaluations ruled 
out cytomegalovirus infection, infectious mononucle-
osis, syphilis, toxoplasmosis, rubella, and HIV. There 
was mild anemia (Hb = 10.6 g/dL; mean corpuscular 
volume = 74.3 fL). 
Curiously, high titles of thyroglobulin antibodies 
(1125.3 IU/mL) were detected when he was 0.87 ye-
ars old. Subsequently serum levels of antithyroid anti-
bodies (thyroglobulin and thyroperoxidase antibodies) 
were normal but since the age of 8.3 years they have 
increased again. 
Thyroid scintigraphy with 131I showed a gland with 
normal position, size and morphology, while scinti-
graphy with 99mTc identified a normal captation after 
2 hours (13%; normal range: 8%-18%), and a reduced 
captation after 24 hours (6%; normal range: 20%-48%). 
A brain computed tomography showed reduced 
ventricles and a bilateral posterior hypodense extra-axial 
collection. When he was 7 years old, an electroencepha-
logram revealed irregular slow-wave activity compatible 
with diffuse brain suffering. 
Re-evaluation of thyroid function when he was 1.47 
and 1.64 years old, identified high serum T3, low total 
and free T4, and TSH values progressively higher (Ta-
ble 1). The increase of serum TSH during his follow-up 
prompted the introduction of levothyroxine at a dose 
of 50.0 mg/m2/day, posteriorly increased to 94.9 mg/
m2/day (corresponding to 3.75 mg/kg/day when he 
was 11.5 years old). Treatment with levothyroxine was 
associated to improvement in thyroid function with nor-
malization of serum T3, progressive increase of free T4, 
normalization of TSH, and maintenance of low total T4, 
as showed by the laboratory evaluation results obtained 
at the ages of 8.75 and 11.6 years (Table 1). On the other 
hand, it was not easy to evaluate the clinical effects of the 
treatment due to the patient’s severe neurologic impair-
ment. Meanwhile we noticed that during the 10.5 years 
of treatment with levothyroxine there was a gradual wor-
sening of the weight deficit from – 1.82 to – 5.09 SDS. 
Table 1. Summary of the findings of thyroid function tests performed at different ages
Age Total T3 (ng/dL) Total T4 (mg/dL) Free T4 (ng/dL) TSh (mU/mL)
7 months old 285.3 (100.0 – 260.0) 4.9 (7.0 – 15.0) 0.50 (0.7 – 1.9) 4.50 (0.25 – 4.0)
1.47 years old 337.0 (70.0 – 200.0) 3.4 (6.4 – 13.3) 0.50 (0.6 – 1.54) 6.80 (0.5 – 4.2)
1.64 years old 275.0 (105.0 – 269.0) 4.1 (5.6 – 10.0) 0.50 (0.7 – 1.8) 9.40 (0.5 – 5.0)
8.75 years old* 235.0 (94.0 – 241.0) 3.3 (6.4 – 13.3) 0.67 (0.7 – 1.5) 2.67 (0.6 – 6.3)
11.6 years old* 166.0 (94.0 – 241.0) 5.5 (6.4 – 13.3) 0.85 (0.7 – 1.5) 1.29 (0.5 – 4.9)
Normal reference ranges in parenthesis.
* : At these ages the patient received treatment with levothyroxine. 
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Lipid profile was evaluated when the patient was 
8.75 years old. At that moment he was treated with 
levothyroxine (33 mg/m2/day) and his thyroid func-
tion was characterized by T3 in the upper limit of the 
normal range, low total and free T4, and normal TSH 
(Table 1). Lipid profile was normal: total cholesterol = 
180 mg/dL, LDL = 101 mg/dL, HDL = 44 mg/dL 
and triglyceride = 62 mg/dL. 
Molecular study of the patient identified the inser-
tion of a G nucleotide at the position 630 (630insG) in 
the coding region in exon 1 of MCT8. The mutation 
caused a frameshift in exon 1 and truncated the pro-
tein at codon 240, as shown in figure 1. His mother is 
heterozygous for this mutation and his asymptomatic 
brother does not carry the mutation. As this insertion 
has not been seen in 50 healthy control men, polymor-
phism was excluded. 
Thyroid function serum evaluation of his mother, he-
terozygous for the mutation and asymptomatic, showed 
normal TSH (1.82 µU/mL), T3 in the upper limit of nor-
mality (199 ng/dL; normal range: 70-200 ng/dL), nor-
mal T4 (7.1 µg/dL), and low free T4 (0.63 ng/dL; nor-
mal range: 0.7-1.5). Antithyroid antibodies were absent. 
of D3 (9). These compensatory mechanisms may work 
acutely but may fail to protect the brain during chronic 
deprivation of TH (9). On the other hand, even during 
the decrease of serum T4 some brain regions or cell 
types, but not others, are capable of maintaining T3 le-
vels, what raises the concept of region-specific compen-
sation to low serum TH (9). The developing brain has 
a very limited capacity to compensate for low TH (9).
Friesema and cols. were the first to report patients 
with resistance to TH due to a transporter defect (4). 
The authors reported mutations in MCT8 in five young 
boys aged 1.5- 6 years with severe psychomotor retar-
dation and strongly raised serum T3 concentrations. 
These patients were characterized clinically by severe 
proximal hypotonia, poor head control, lack of verti-
calization, no targeted grasping, involuntary writhing 
movements, movement-induced increase in distal mus-
cle tone, and severe mental retardation with lack of 
speech development and rudimentary communicative 
skills. This group of patients did not show any sign or 
symptom of hypothyroidism. Their thyroid laboratory 
evaluations showed serum levels of T4 and free T4 at 
the lower limit of the normal range, TSH concentra-
tions varying from normal to high and remarkably in-
creased serum T3. The five patients harbored loss-of-
-function mutations of the X-linked MCT8 gene (4). 
The neurologic characteristics of our patient have 
been described in association to inactivating mutations 
of MCT8, specially the substitution of global hypotonia 
for a global hypertonia. Schwartz and cols., studying six 
families with Allan-Herndon-Dudley syndrome stated 
that the progression to spastic paraplegia is notable (7). 
During infancy and early childhood the main neuro-
muscular findings are hypotonia and decreased muscle 
mass, affecting specially the neck. Truncal hypotonia 
persists into adolescence and adult life whereas the 
limbs, hands, and feet become hypertonic, spastic, and 
contracted, and/or dystonic and fixed in position (10). 
At this point a neurologic exam may identify hyperre-
flexia at the large joints, clonus, and Babinski signs (7). 
With respect to the crisis observed in our patient, they 
seem to be common in patients with the syndrome and 
are classified by some authors as paroxysmal kinesigenic 
dyskinesias that may be provoked by stimuli like chan-
ging clothes or diapers (11).
We observed that the growth of our patient, who 
was born with normal length (51 cm), was normal du-
ring the first 20 months of age. These data were also re-
ported by others and suggest that MCT8 is not impor-
Figure 1. Nucleotide and amino acid sequences of human MCT8 and the 
alterations introduced by the mutation insG630 (underlined). Downstream 
of the G insertion, the wild-type amino acid sequence is indicated in black 
and the mutant sequence in gray. The insertion results in a frame-shift with 
truncation of the protein at codon 240 (*). 
DISCUSSION
TH have crucial roles in brain development inclu-
ding the control of cell proliferation, specification of 
neural and glial cell fate, migration and synaptogene-
sis (9). During hypothyroid states it is important that 
the intracellular concentration of T3, the active TH, 
be maintained at a safe range, especially in vital organs 
like the brain. In the brain this is achieved by means of 
increased brain uptake of serum T3 through increased 
action of transporters like MCT8, increased conversion 
of T4 to T3 through increased action of D2 and decre-
ased conversion of T3 to T2 through reduced action 
New mutation in MCT8 in a Brazilian boy
601 ATG CTG CTA GAG GAG GAA AAG GAA AAA AAG 
201  M   L   L   E   E   E   K   E   K   KN  
631 TCG CCA AGT GGA GTT CCA AGC AGC ATG GGT 
211  SR  SA  MW  GV  PQ  SV  GE  VF  PQ  SA
661 CGG AGC CCT CGC GAT GGG TAT GAT CTT CTT
221  RG  SA  PL  RA  DM  GG  YM  DI  LF  LF
691 CTG TTC TCC CAT TGT GAG TAT ATT CAC TGA
231  LC  FS  SP  HI  CV  ES  YI  IF  HT  *D 
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tant for TH transport in bone cells (7,12,13). Similarly, 
the patient evaluated by Herzovich and cols. grew nor-
mally during the first two years of life, and his bone ma-
turation was advanced (bone age was 30 months when 
his chronologic age was 18 months) (14). In agree-
ment with these results, the study of Williams and cols. 
identified that although MCT8 mRNA is expressed in 
chondrocytes, osteoblasts and osteoclasts at all stages of 
cell differentiation, T3 availability during skeletal deve-
lopment seems to be limited by D3-mediated catabo-
lism rather than by MCT8-mediated cellular uptake or 
D2-dependent T3 production (1). The advanced bone 
maturation is one characteristic of hyperthyroidism in 
children and adolescents. Therefore the increased bone 
maturation identified by Herzovich and cols. suggests 
that the inactivation of MCT8 and the consequent in-
crease of serum T3 creates a hyperthyroid-like state for 
bone tissue (14). 
We also noted a disproportion between the height 
and the weight of our patient. This disproportion was 
characterized by superior height in relation to his wei-
ght as exemplified by the discrepancy between the hei-
ght and weight SDs at the ages of 9 months (+ 0.89 
and – 0.36, respectively), and 20 months (+ 0.33 and 
– 1.82, respectively). In the six families with Allan-
-Herndon-Dudley Syndrome studied by Schwartz and 
cols. the authors observed that in 19 out of 29 male 
patients (65.5%) at all ages the weight percentile was be-
low the third percentile (7). Herzovich and cols. found 
increased levels of muscle metabolism markers (serum 
ammonium and lactic acid) in their patient with inactive 
MCT8 (14). Aiming to evaluate the influence of serum 
T3 on the body mass index Wémeau and cols. studied 
the effects of treatment with propylthiouracil (PTU) 
(200 mg/day) in an undernourished 16 year-old boy 
with a loss of function mutation of MCT8 (15). After a 
period of treatment with PTU levothyroxine was added 
to the treatment at doses of 50, 75, and 100 mg/day 
(15). While treatment with PTU alone reduced free T4, 
normalized free T3, and increased TSH serum levels, 
the introduction of levothyroxine, especially in the 100 
mg/day dose, allowed TSH and free T4 levels return to 
those levels obtained before the introduction of PTU 
(15). More importantly, this strategy improved body 
mass index as a consequence of the increase in the rate 
of weight gain from 200 g/year to 3 kg/year (this tre-
atment had no effect on cerebral disturbances and the 
psychomotor retardation) (15). Thus we can speculate 
that increased serum T3 also generates a hyperthyroid-
-like state in the muscle and adipose tissue, capable of 
preventing the adequate weight gain. 
In our patient the normal lipid profile in spite of 
low total and free serum T4 levels suggests an increased 
action of T3 in the liver. We can speculate that the in-
creased action of T3 in the liver hindered the elevation 
of serum LDL and triglyceride that could be expected 
in the context of hypothyroidism. Interestingly, serum 
levels of sex hormone-binding protein, a protein syn-
thesized in the liver under the stimulus of TH, was per-
sistently elevated in the patient described by Herzovich 
and cols. (14). 
The patient we have described, like other patients 
with inactivating mutations of MCT8, had no signs 
or symptoms typically associated to congenital hypo-
thyroidism (prolonged jaundice, umbilical hernia, bra-
dycardia, growth retardation, myxedema and tendency 
to overweight or obesity) (12). This clinical finding 
reinforces the concept that tissues like bone, fat and 
liver are not as dependent on MCT8 for TH transport 
as the brain is. 
In our patient, and also in those described by other 
authors, the high serum values of TSH associated to 
high serum T3 suggest that the negative feedback of 
T3 on the pituitary is compromised probably because 
a smaller amount of T3 is capable to reach its nucle-
ar receptors. Maranduba and cols. studied four adult 
Brazilian patients of the same family and showed that 
the protein originated from the mutated MCT8 has 
a low capacity to promote T3 transport into the cells 
(16). This finding may have severe consequences to the 
brain, a tissue which is very dependent on MCT8 for 
T3 transport into cells. It is noteworthy that the intro-
duction of levothyroxine resulted in reduction of T3 
and TSH serum levels. We believe that the effect of 
levothyroxine may be attributed to a better pituitary 
negative feedback capable of reducing TSH secretion 
and consequently the conversion of T4 to T3. We must 
remember that in the pituitary almost three quarters of 
intracellular T3 originates from the conversion of T4 
and the remainder derives from circulation. However, 
alterations in thyroid profile associated to mutations 
in MCT8 are still a reason for debate. Maranduba and 
cols. identified that the increase of serum T3 is related 
to the reduction of its intracellular clearance as a result 
of decreased entry of the hormone into cells that me-
tabolize it through D3 (16). However, studies in Mct8 
knockout mice show that T3 generation by D1 and D2 
is increased, which has a consumptive effect on serum 
New mutation in MCT8 in a Brazilian boy
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total and free T4 levels. In these mice pituitary resistan-
ce to T3 was also identified (15). 
In our patient the novel mutation 630insG in the 
coding region at exon 1 of MCT8 resulted in a fra-
meshift with truncation of the protein at codon 240. 
Probably the mutation 630insG inactivated MCT8 
completely. As the insertion was not observed in 50 
healthy control men polymorphism was excluded. The 
functional effect of this novel mutation has still to be 
determined. On the other hand, Frints and cols. repor-
ted a similar mutation 630insA in one among the 13 
families studied with individuals affected by X-linked 
mental retardation (17). Mutation 629insA caused a 
frameshift in exon 1 and introduced a premature termi-
nation codon in exon 2 of MCT8 (17). The mutations 
of MCT8 encompass large deletions, smaller frameshift 
deletions, deletions or insertions of 1-amino acid, non-
sense mutations and missense mutations (2). Studies 
suggest that there is a genotype-phenotype correlation 
in patients with mutations in MCT8 (2).
Our patient evolved with variable levels of anti-
thyroid antibodies. Both thyroglobulin and thyropero-
xidase antibodies were detected at the age of 9 months 
and again when he was older than 8.3 years. One male 
patient with inactivating mutation of MCT8 described 
by Dumitrescu and cols. had been diagnosed with in-
sulin-dependent diabetes mellitus at 3 years of age, and 
the patient had a maternal aunt, an uncle and one gran-
dmother with autoimmune thyroid disease, evidenced 
by positive thyroglobulin and thyroperoxidase antibo-
dies (5). The other patient studied by the same group 
had a maternal grandfather with mild TSH elevation 
due to autoimmune thyroid disease confirmed by po-
sitive thyroperoxidase antibodies (5). We believe that 
current knowledge does not allow us to associate the 
inactivation of MCT8 to the risk of autoimmunity. Pro-
bably the description of new patients with inactivation 
of MCT8 and a deeper understanding about MCT8 
functions and interactions will help in this matter.
The mother of the patient is heterozygous for the 
mutation of MCT8 and, although clinically asymptoma-
tic, showed mild thyroid function abnormalities (nor-
mal serum TSH and total T4, serum T3 in the upper 
limit of normality and low free T4). Abnormal thyroid 
profile with high serum T3 levels may be present in 25% 
of female carriers of the MCT8 mutation (17). Studies 
performed by Dumitrescu and cols. to clarify the rea-
son for the thyroid phenotype in heterozygous women 
suggested that both dominant-negative effect and ha-
ploinsufficiency are mechanisms responsible for the do-
minant expression of the thyroid phenotype (5). The 
authors observed that apparently there is no preferential 
X inactivation of the two alleles (5). The phenotype of 
heterozygous females for mutations of MCT8 encom-
passes from asymptomatic patients to those with mild 
mental retardation (5,14,17). However, Frints and cols. 
reported the first female patient with the Allan-Hern-
don-Dudley syndrome (17). This patient was severely 
developmentally retarded and showed elevated serum 
T3 and free T3 due to a de novo balanced 46,X,t(X;9)
(q13.2;p24) translocation (17). In this patient the com-
plete nonrandom inactivation of normal X chromosome 
impinged the expression of MCT8 (17).
Although new cases of mutations of MCT8 have 
been described, the scarce number of patients precludes 
knowledge about prevalence, clinical manifestations 
and genotype-phenotype correlation of the disease. X-
-linked mental retardation has an estimated prevalen-
ce of 0.1% in males and is related to disturbances in a 
group of 82 genes, including MCT8 (2). Currently, in 
view of the difficult clinical definition of X-linked men-
tal retardation, it is suggested that mutations of MCT8 
be suspected in the context of an abnormal thyroid 
profile characterized by increased T3, low-normal to 
low free T4, low rT3, and normal to elevated TSH se-
rum levels (2). The measurement of serum free T3 is 
considered the better method for screening high-risk 
populations, such as children with developmental delay 
and hypotonia (7).
In summary, we describe a male patient with a novel 
inactivating mutation of MCT8. The patient was cha-
racterized clinically by severe neurologic impairment 
(initially manifested as global hypotonia later evolving 
with generalized hypertonia and spastic quadriplegia), 
normal growth during the first two years of life, redu-
ced weight gain during his infancy and childhood and 
absence of the typical signs and symptoms of hypo-
thyroidism. His laboratory evaluations disclosed high 
T3, low total and free T4, and mildly elevated TSH 
serum levels. Treatment with levothyroxine resulted in 
better thyroid function tests (with normalization of to-
tal T3 and TSH, a progressive increase in free T4, and 
the maintenance of low total T4 levels) but no clear cli-
nical benefit could be recognized. Our results reinforce 
the concept that the role of MCT8 in the intracellular 
transport of TH is tissue-dependent: neurons seem to 
be highly dependent on MCT8, while the bone, adipo-
se tissue, muscle and liver are clearly less dependent on 
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MCT8 and may therefore suffer the consequences of 
the exposition to high serum T3 levels. 
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